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Summary.-Six anilinoacridine derivatives have been tested for the ability to act as
radiosensitizers. Two gave good sensitization at concentrations of 100 pM or less.
Both ofthese are known to possess significant activity against experimental tumours,
and one (m-AMSA) is in Phase II clinical trial as a chemotherapeutic drug. Anilino-
acridines may have potential as drugs with both a chemotherapeutic and radio-
sensitizing role. In spite of their structural similarity, the 2 derivatives which sensi-
tize do so by different mechanisms. Compound VI behaves like a typical hypoxic cell
sensitizer but Compound I (m-AMSA) interferes with the accumulation of sublethal
damage in either the presence or absence of 02. The latter also displays a post-
irradiation sensitizing effect. Differences in mechanism may be related to the relative
DNA-binding abilities and electronic differences between the 2 drugs.
RESEARCH aimed at improving the
radiotherapeutic management of cancer
patients can be considered in two broad
categories. Firstly, evidence is sought of a
therapeutic gain from the combination of
radiotherapy and alternate treatment
modes, particularly chemotherapy (IAEA,
1977; Leenhouts & Chadwick, 1978).
Secondly, there is research attempting to
increase the intrinsic tumour response to
radiation, which includes the use of
chemicals to sensitize hypoxic cells selec-
tively. One group of hypoxic cell sensi-
tizers, the nitro-imidazoles, has received
detailed experimental study, and recent
cautious clinical application (Fowler et al.,
1976). The finding that these nitro-
imidazoles (or, possibly, their metabolites)
are preferentially toxic to hypoxic cells
has provided a potential link between
radiosensitizers and chemotherapy (Hall
& Roizin-Towle, 1975; Mohindra & Rauth,
1976; Stratford & Adams, 1977). Cells
subjected to sufficiently severe hypoxia
stop progressing through the cell cycle, an
effectwhich canalsobeinducedintumours
byother conditions such asthedeprivation
ofcertain nutrients, cellular over-crowding
and non-optimal temperature and pH.
Most available anti-tumour drugs are more
effective against cells in cycle than those
out of cycle, and the non-cycling, clono-
genic cells of a tumour may present a
major problem in current therapy. Nitro-
imidazoles may prove to be useful against
these non-cycling cells, although Brown
(1977) has pointed out that hypoxia rather
than the non-cycling of the cells may be
responsible for the preferential toxicity.
There has been recent interest in a
series of 9-anilino-acridines which are
tumour-inhibitory (Denny et al., 1978, and
references therein). One member of the
series, m-AMSA (NSC249992) is at present
in Phase II clinical trial under the auspices
ofthe AmericanNational Cancer Institute.
This novel aminoacridine derivative has
comparable degrees of cytotoxicity to-
wards both cycling and non-cycling
Chinese hamster ovary cells in culture
(Tobey et al., 1978). The aminoacridines
quinacrine and acriflavine are already
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known to possess radiosensitizing ability
in a variety of experimental systems, in-
cluding some using mammalian cells
(Arlett, 1970; Fuks & Smith, 1971;
Bleehan et al., 1974). Both quinacrine and
acriflavine intercalate between the base
pairs in twin-helical DNA where, it is
suggested, they inhibit the function of
"'repair enzymes". Actinomycin D, which
possesses a planar tricyclic ring system
comparable to that of the aminoacridines,
is also an intercalating agent and an effec-
tive sensitizer of mammalian cells in vitro
(Elkind & Whitmore, 1967). This sensitiz-
ing ability may be the reason for the en-
hanced tissue response in radiotherapy
patients who have received the drug
(Piro et al., 1975).
Studies on representative tumour-active
9-anilinoacridines (including m-AMSA)
have shown that these compounds are
also DNA-intercalating agents (Waring,
1976) and clearly such agents should be
examined forradiosensitizing ability. After
encouraging preliminary results with m-
AMSA in a bacterial system, a group of
9-anilinoacridines was examined with the
ultimate aim of developing quantitative
molecular structure-activity relationships
(QSAR) for the radiosensitizing abilities
of members of this class of compound.
Development of QSAR for the sensitizing
properties of these compounds would aid
in the selection of further analogues for
more extensive testing. Work in progress
with some 9-anilino-acridines has demon-
strated the existence of such QSAR for
both in vivo anti-tumour activity and
mutagenic potential. This paper reports
the sensitizing abilities of the limited
number ofcompounds tested so far and an
unexpected difference in the mechanism
ofaction ofthe 2 most effective sensitizers.
MATERIALS AND METHODS
Six 9-anilinoacridine derivatives (I-VI)
were selected, and prepared as described
elsewhere (Cain et al., 1975; Atwell et al.,
1977; Denny et al., 1978). These include
the clinical-trial candidate m-AMSA (I)
and, as many excellent radiosensitizers con-
tain a nitro group, the tumour-inhibitory
3-nitro analogue II. Because of the relative
insolubility of II, a more soluble tumour-
inhibitory 3-nitro derivative (III) was exam-
ined, as was an inactive compound (IV)
which has a nitro group in an alternative
position. Two other derivatives with different
electron-withdrawing groups in the same posi-
tion as the nitro group of (IV), the inactive
sulphonamide (V) and the tumour-inhibitory
carboxylic acid derivative (VI) were also
included. Solutions of the salts of these com-
HN
H 3 X
Derivative
I
II
NHSO2CH3
NHSO2CH3
NH
III NHSO2(CH2)2NHC"
NH2
IV
V
VI
NO2
SO2NHCH3
COOH
OCH3 H
OCH3 NO2
H
H
H
H
NO2
H
H
H
CH3SO3
C1-
2C1-
Ci-
CI-
C1-
642RADIOSENSITIZATION BY 9-ANILINOACRIDINES
pounds were prepared in distilled water just
before use, and diluted into the bacterial
suspension to provide the appropriate con-
centration. It should be noted that the
solubility of the drugs was reduced 4- to 10-
fold in the phosphate-buffered suspensions
(66mM phosphate salts, pH 7-0 +0-1). Drug
toxicity, and the ability of the drug to
sensitize when present at the time of irradia-
tion, were evaluated with E. coli B/r cells
grown to late log phase in tryptone-glucose-
yeast (TGY) medium at 37°C. The cells were
filtered, washed, and suspeinded in buffer at a
density of about 107 cells/ml. After exposure
to the drug, to radiation, or to the combina-
tion ofdrug plus irradiation, cell survival was
estimated by dilution of the cells into buffer
and plating out on TGY agar followed by
overnight incubation at 37°C.
Irradiations were carried out at room tem-
perature using a Gammacell-220 60Co source
and a dose rate of , 10 krad/min. Moist air
or N2 (less than 12 parts in 106 02 as deter-
mined in the effluent gas by a Hersch cell)
was bubbled through the suspensions as
required. For experiments in which the post-
irradiation effect of the drug was tested, the
growth medium contained a minimal salts
medium (4-4 g Na2HPO4, 2-7 g KH2PO4,
1-0 g (NH4)2SO4, 0-14 mg FeSO4, 100 mg
MgSO4.7H20, and 5 mg Ca(NO3)2 per litre
of distilled water). Late log-phase cells were
filtered, washed and suspended in this
minimal-salts medium. The suspension was
then irradiated for 2-5 or 4 min (25 or 40 krad)
and then supplemented with glucose (0-2%),
casamino acids (0-5 g/l) and thiamine (1 mg/l)
within half a minute. Drug was also added
within this period ifrequired, and the suspen-
sion was incubated at 40C or 37°C. Aliquots
were taken at intervals and diluted and plated
out as above.
RESULTS
All the anilinoacridines tested were
degraded by radiation. This degradation,
which could be conveniently monitored by
the decrease in optical absorbance in the
spectral region 400-450 nm, occurred
whether in the presence or absence of
bacteria, and was somewhat greater in
air than in N2. Thus, 50% loss of the
chromophore was found after 20 krad (in
air) and 30 krad (in N2) for Compound VI.
With Compound I, the equivalent doses
were 60 and 100 krad. This degradation is
not surprising, since it is known that the
9-anilinoacridines suffer chemical cleavage
in biological media which contain nucleo-
philic species (Cain et al., 1976; Wilson
et al., 1977). The products of radiation-
induced degradation were less toxic than
the parent compounds in each case. At the
radiation doses used in our experiments,
some degradation would be expected, and
all the concentrations quoted should be
regarded as initial values.
Because of extreme insolubility, IV
couldnotbetested at concentrationsabove
1 ztM. The testing ofCompounds II and III
was limited to concentrations below 10 pM
because ofunacceptable toxicity at higher
levels. At the concentration limits imposed
on Compounds II-IV, no radiation sensi-
tization could be detected. Of the remain-
ing derivatives, V and VI were not toxic
(defined as less than 20% loss of viability
of the bacterial cell population after a 1 h
exposure to the agent) in buffer up to their
solubility limit ofabout 50 pM. Compound
I had an upper solubility limit of 150KM,
but toxicity reduced the highest concen-
tration that could be used to 100 pM. After
exposure ofthe cells in buffer to 100 Mm of
I for 1 h, an 80% loss of viability was
recorded. However, with cellssuspended in
supplemented minimal-salts medium (used
in the experiments to test for post-
irradiation sensitization) 100 Mm of I
showed no detectable toxicity.
Compound I (m-AMSA)
Fig. 1 shows that I sensitized E. coli
B/r to the sterilizing effects of radiation
when present at the time of irradiation.
Sensitization occurred in both air and N2,
and was due to a reduction ofthe shoulder
on the survival curve. The sensitizing
effects of the various concentrations of I
were fully expressed only if the cells were
exposed to the drug for about half an hour
before irradiation. A standard protocol
was developed in which 30min pre-
exposure to the drug was allowed before
irradiation was begun. Thus irradiations
in air were performed between 30 and 35
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FIG. 1.-The effect ofCompound I on the sur-
vival of E. Coli B/r when present at the
time ofirradiation. Cellsirradiatedinbuffer.
0, N2 alone; ,N2+ 25,UM drug; A, N2+
501uM drug; 0, N2+ 100/LM drug; C]i, air
alone; *, air+lOO,M drug.
min after initial exposure to the drug, and
irradiations in N2 between 30 and 45 min.
The number of viable cells at the start of
irradiation was taken as the initial value
in the calculation of surviving fractions.
Removal of the shoulder on the survival
curve was complete at a concentration of
100 pM of I, and partial at lower concen-
trations. Although the highest concentra-
tion shows some toxicity towards E. coli
B/r in buffer, as noted above, control
experiments in which cells were sham-
irradiated indicated that the loss of
viability during the irradiation period did
not exceed 20%. These losses are expected
to have no significant effect on the survival
curve, which extends over 3 orders of
magnitude. When cells were exposed to
100 p-M of I for 30 min and then filtered
and washed before being resuspended in
buffer without drug and irradiated, the
survival curve was identical to that for
cells which had never been exposed to the
hours after irradiation
FIG. 2.-The effect of Compound I when
added to E. coli B/r immediately after irra-
diation in non-supplemented growth
medium. At zero time the medium was
also supplemented (see text) and incubated
at 37°C. Open symbols refer to media con-
taining no drug, closed symbols refer to
media containing 1OOUM drug. Cellnumbers
in each experiment have been normalized
to give the same values at zero time.
drug. Thus, toxic effects during the
30min exposure to the drug before irradia-
tion did not produce a population ofdrug-
resistant cells with altered radiation sus-
ceptibility.
The effect of addition of 100 tuM of I
immediately after 25 krad irradiation,
under conditions which promote growth in
cell numbers (supplemented minimal-salts
medium), is shown in Fig. 2. Under these
conditions, 100 ,M of I is not toxic to
unirradiated controls. The growth curves
for irradiated bacterial suspensions are
displaced in time, but eventually become
parallel to those for unirradiated bacteria.
At any given time after irradiation, there
were fewer viable cells in irradiated sus-
pensions than in an unirradiated suspen-
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sion which had the same number of viable
cells at zero time. The presence ofI further
decreased the number of viable cells in
irradiated suspensions by a factor ofabout
2- (a range of 2-3 in 3 separate experi-
ments). One to one and a half hours was
required for the full expression of this
enhancement of radiation damage. In-
creasing the dose from 25 to 40 krad did
not give a significantly greater post-
irradiation effect. Active metabolism was
required to observe an enhancement, since
incubation at 4°Cfor 1 h produced no post-
irradiation effect, even if the cells were
subsequently incubated at 37°C.
Compound VI
When present at the time ofirradiation,
Compound VI was also capable ofsensitiz-
ing E. coli B/r to the effects of radiation
in the absence of02, butit didnot sensitize
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FIG. 3.-The effect of Compound VI on the
survival of E. coli B/r when present at the
time ofirradiation. Cells irradiated in buffer.
Lines A and B are the response in N2 and
air, respectively, in the absence of drug;
*, air+50OiM drug; , 0, N2+50,UM
drug. The variability found in N2 + drug is
discussed in the text and in Fig. 4.
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FiG. 4. The reproducibility of the enhance-
ment ratio for various concentrations of
Compound VI in N2; oxygen enhancement
(OER) is also indicated. The line drawn is
not intended to indicate a best fit.
in air (Fig. 3). With this compound, sensi-
tization of hypoxic cells occurred via an
increase in the slope of the survival curve
rather than reduction of the shoulder.
Again, a standard protocol was used in
all experiments, the freshly suspended
cells in buffer being exposed to the drug
for 30 min before irradiation. In spite of
this, considerable variability was seen in
the hypoxic enhancement ratio (the ratio
of the slopes of the survival curves with
and without drug) in experiments which
were carried out close to the solubility
limit of 50 juM, as shown in Fig. 4. The
reason for this is not clear, but tempera-
ture and light sensitivity of the drug do
not appear responsible. Fig. 4 also shows
that some sensitization was seen at con-
centrations as low as 15 juM. Compound
VI was tested for post-irradiation effects,
but none were observed, even at the upper
concentration limit of 50 VM (Fig. 5).
Compound V
At the solubility limit for this compound
(40-50 ,uM) slight sensitization was found
both in N2 and in air. The effect is real and
reproducible, but so slight that a large
number ofexperiments would be needed to
decide with certainty whether the effect
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FIG. 5.-The effect of Compound VI when
added to E. coli B/r immediately after irra-
diation in non-supplemented growth
medium. At zero time the medium was
supplemented (see text) and incubated at
37°C. Open symbols refer to media contain-
ing no drug, closed symbols refer to media
containing 50,M drug. Cell numbers in each
experiment have beennormalized togivethe
same values at zero time.
involves a change in the slope of the sur-
vival curve or a decrease in the shoulder.
However, the result is worthy of mention,
for, unlike the other two derivatives I
and VI, Compound V is not tumour-
inhibitory in in vivo tumour screens
(Denny et at., 1978). No post-irradiation
sensitization was found for this compound.
DISCUSSION
Effective sensitization of E. coli B/r to
radiation occurs with Compound I (m-
AMSA) both in the presence and absence
Of 02. Thus, Compound I is unlikely to
produce atherapeutic gain in radiotherapy
unless it is taken up selectively by tumour
cells. There is some evidence of this
(Shoemaker et al., 1978) as there is for
the selective uptake of the aminoacridine
quinacrine (Ackerman et at., 1965; Ang-
hileri, 1966). Further experiments with
mammalian cell systems are needed to
clarify this point. Compound VI should
selectively sensitize tumours that possess a
significant fraction of hypoxic cells at the
time of irradiation, if the bacterial results
are indicative for tumours in vivo. The
results are sufficiently encouraging to
warrant a detailed investigation of the
class of 9-anilinoacridines as sensitizers
of mammalian cells, both in vitro and in
vivo. Bacterial results are of doubtful
clinical relevance and mammalian data
are clearly required.
A most striking aspect of this pre-
liminary work is thefactthat the two most
effective compounds, I and VI, sensitize
the bacterial cells to radiation in different
ways. The carboxylic-acid derivative VI
appears to act as a typical hypoxic-cell
sensitizer. It increases the lethal effects of
radiation to cells in the absence of 02,
increasing the survival-curve slope, but
has no effect in the presence of 02. The
compound does not show any post-
irradiation effects. In contrast, Compound
I acts byeliminatingthe shoulderobserved
on the survival curve at low doses, which
implies a removal ofthe ability to accumu-
late sub-lethal damage. This effect occurs
both in the presence and absence of 02.
Compound I is also an effective post-
irradiation sensitizer, an ability similar to
that displayed by quinacrine (Fuks &
Smith, 1971). For quinacrine, there is
evidence that it interferes with the repair
of damaged DNA, probably via drug
intercalation into the DNA base pairs.
The maximum post-irradiation enhance-
ment of radiation damage found with
quinacrine was far greater than that seen
in this study with I, but these maximum
effects were observed at toxic quinacrine
levels. When the two compounds are com-
pared at non-toxic levels (100,UM and
below) quinacrine appears to be about 3-
to 5-fold more effective than I. If drug
intercalation into DNA is indeed involved
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in post-irradiation sensitization, these
differences are not surprising, because
quinacrine binds much more strongly to
DNA than does Compound I (Cain et al.,
1978). The post-irradiation enhancement
shown by I clearly involves slow processes
(see Fig. 2), and is inhibited at 4°C.
Thisimpliesthetypeofrepairoperationally
defined as Type III by Town et al.
(1973).
The simplest explanation consistent
with the observations is that I interferes
with repair enzymes which otherwise
would eliminate potentially lethal cell
damage after irradiation. As a result of
thisinterference, potentially lethal damage
can be expressed when the cells are stimu-
latedtodivide. No datahavebeenreported
on sensitization by quinacrine when it is
present at the time of irradiation, so that
no comparison with the observations of
Fig. 1 can be made. However, if it is
accepted that the accumulation of sub-
lethal damage is also under the control of
a repair enzyme system, then the results
are reasonable.
The reasons for the different sensitizing
effects shown by these two similar com-
pounds (I and VI) is not clear. It is known
thatCompoundIbindsmuchmorestrongly
to calf thymus DNA than does the car-
boxylic acid VI (Baguley, personal com-
munication), and there are also substantial
differences in charge distribution between
the two derivatives. The pKa of the acid
group of VI is 4-6 (Atwell, personal
communication), and at the pH of the
buffer used (7 0 + 0 1) it will exist almost
entirely as the anion. The electronic
nature of groups in the anilino ring of the
9-anilinoacridines has a marked effect on
their anti-tumour activity (Atwell et al.,
1972); the same appears to be true for
their radiosensitizing properties.
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